Carbamazepine [clinicaltrials_resource:051b8d6a355258bcb1c4b756be55ce20]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT00084981 [clinicaltrials_resource:02ff15b2191e2e4d495e9977caee9c24]eligibility for clinicaltrials:NCT00331643 [clinicaltrials_resource:04e94b8a43da0e6fb95715b99650bb9c]eligibility for clinicaltrials:NCT00363272 [clinicaltrials_resource:0b0953eac77c878adc10605e4ff5b90a]eligibility for clinicaltrials:NCT00087386 [clinicaltrials_resource:1dcdf36881b638564b2dbe9dd1a090ed]eligibility for clinicaltrials:NCT00107536 [clinicaltrials_resource:273f28a85c6566d76ff76854cd53b9fb]eligibility for clinicaltrials:NCT00134069 [clinicaltrials_resource:31c44eb02996a6c0ff1a0b62791f3b16]eligibility for clinicaltrials:NCT00096434 [clinicaltrials_resource:37418a0101b58e4f9df7e58cb41ae0b1]eligibility for clinicaltrials:NCT00118157 [clinicaltrials_resource:38c27da684633d4e18d079b4d14c3854]eligibility for clinicaltrials:NCT00397787 [clinicaltrials_resource:44f7445b33573724f39d2c3350c2edd2]eligibility for clinicaltrials:NCT00617708 [clinicaltrials_resource:5779b97f6e8f19f4261bc4fbf6ffca8f]eligibility for clinicaltrials:NCT00499473 [clinicaltrials_resource:5ca8ad21c29b46d218fd2f449ba803f2]eligibility for clinicaltrials:NCT01159301 [clinicaltrials_resource:655c301682c937d4832cd67c710c7054]eligibility for clinicaltrials:NCT00316849 [clinicaltrials_resource:69d7b3809a98c9605562307ed5865877]eligibility for clinicaltrials:NCT00316953 [clinicaltrials_resource:74b44c39daeec707e0c2ba296d4082a1]eligibility for clinicaltrials:NCT01626391 [clinicaltrials_resource:764092380051a65411a8e3d9b1d9b70a]eligibility for clinicaltrials:NCT00096265 [clinicaltrials_resource:7ed2edd609e0b9f3f33e73134b6e3415]eligibility for clinicaltrials:NCT00378911 [clinicaltrials_resource:90e2573b962fa7b00d8bc3d81c673d4b]eligibility for clinicaltrials:NCT00096499 [clinicaltrials_resource:a07408bbc65c5b2266e419ce0526be68]eligibility for clinicaltrials:NCT00906360 [clinicaltrials_resource:ab102d1f180ab3114d9eef4e4cd8cffd]eligibility for clinicaltrials:NCT00387920 [clinicaltrials_resource:ae648621e7eda92397728786d3a31e65]eligibility for clinicaltrials:NCT00398112 [clinicaltrials_resource:baa879f991df91a619bf63a4eb76ddf8]eligibility for clinicaltrials:NCT00070525 [clinicaltrials_resource:bbc57e24ec459e18f6e64dc2c331a766]eligibility for clinicaltrials:NCT00119236 [clinicaltrials_resource:d8177edb3af609f1c135ac1b3cd473fc]eligibility for clinicaltrials:NCT00101270 [clinicaltrials_resource:eb230e0b5e77e6f091aa9b3892782ee6]eligibility for clinicaltrials:NCT00058253 [clinicaltrials_resource:efa3f75555d306a863b90f3f66cc9ff9]eligibility for clinicaltrials:NCT00243035 [clinicaltrials_resource:ffb5cadaf629081416f69bb81c6c107d]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Carbamazepine Treatment for Cocaine Dependence - 5 [clinicaltrials:NCT00000191]Pharmacotherapy and Intensive Treatment of Drug Abuse - 1 [clinicaltrials:NCT00000217]Pharmacotherapy and Intensive Treatment - 2 [clinicaltrials:NCT00000218]Carbamazepine Treatment of Cocaine Dependence - 1 [clinicaltrials:NCT00000242]Drug Therapy for Alcohol Detoxification [clinicaltrials:NCT00000441]Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment [clinicaltrials:NCT00004758]Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers [clinicaltrials:NCT00006395]Does Gabapentin and Lamotriginel Have Significantly Fewer Side-Effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly. [clinicaltrials:NCT00007670]clinicaltrials:NCT00021866Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma [clinicaltrials:NCT00142025]The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) [clinicaltrials:NCT00145691]Efficacy and Safety of SPD417 in Treatment of Manic Symptoms in Adults With Bipolar I Disorder [clinicaltrials:NCT00150553]Safety of SPD417 Combined With Other Psychotropic Medications in the Treatment of Bipolar I Disorder [clinicaltrials:NCT00150605]Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy. [clinicaltrials:NCT00150787]Study of Efficacy of Carbamazepine in Therapy of Patients With Moderate Persistent and Severe Bronchial Asthma [clinicaltrials:NCT00153296]The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States. [clinicaltrials:NCT00154323]The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States. [clinicaltrials:NCT00154362]clinicaltrials:NCT00175903Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder [clinicaltrials:NCT00181870]Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania [clinicaltrials:NCT00190892]clinicaltrials:NCT00203567Antiepileptic Drug Carbamazepine in Treatment of Bronchial Asthma [clinicaltrials:NCT00207428]Second-Line Treatment Choice for Epilepsy [clinicaltrials:NCT00208520]Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy [clinicaltrials:NCT00216567]clinicaltrials:NCT00224952A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy [clinicaltrials:NCT00236717]Induction of Drug Metabolism: In Vivo Comparison of Carbamazepine and Oxcarbazepine. [clinicaltrials:NCT00260247]clinicaltrials:NCT00266630Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures [clinicaltrials:NCT00275912]Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures [clinicaltrials:NCT00275925]Pharmacokinetics Study on Nevirapine Resistance in Tanzania [clinicaltrials:NCT00294892]Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder [clinicaltrials:NCT00325286]The Young Adult and Pediatric Bipolar Study [clinicaltrials:NCT00350857]Prediction of Childhood Epilepsy Outcome in Bangladesh [clinicaltrials:NCT00381537]clinicaltrials:NCT00391534clinicaltrials:NCT00438451Study of Hormonal Sideeffects in Patients Taking Levetiracetam, Carbamazepine or Lamotrigine for Epilepsy [clinicaltrials:NCT00460070]clinicaltrials:NCT00467753clinicaltrials:NCT00477295clinicaltrials:NCT00542802
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Carbamazepine [clinicaltrials_resource:051b8d6a355258bcb1c4b756be55ce20]
Bio2RDF identifier
051b8d6a355258bcb1c4b756be55ce20
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:051b8d6a355258bcb1c4b756be55ce20
identifier
clinicaltrials_resource:051b8d6a355258bcb1c4b756be55ce20
title
Carbamazepine
@en
type
label
Carbamazepine [clinicaltrials_resource:051b8d6a355258bcb1c4b756be55ce20]
@en